Search

Aging is a major risk factor for Alzheimer’s disease (AD), the most common cause of dementia worldwide. TDP-43 proteinopathy is reported to be associated with AD pathology is almost 50% of cases. Our exploratory study examined near end-stage (28 months old) mice selectively driving expression of human TDP-43 in the hippocampus and cortex in an APP/PSEN1 background. We hypothesized that hippocampal neuropathology caused by β-amyloidosis with TDP-43 proteinopathy induced in this model, resembling the pathology seen in AD cases, manifest with changes in resting state functional connectivity. In vivo magnetic resonance imaging and post-mortem histology were performed on four genotypes: wild type, APP/PSEN1, Camk2a/TDP-43, and Camk2a/TDP-43/APP/PSEN1. Our results revealed loss of functional coupling in hippocampus and amygdala that was associated with severe neuronal loss in dentate gyrus of Camk2a/TDP-43/APP/PSEN1 mice compared to APP/PSEN1 and wild type mice. The loss of cells was accompanied by high background of β-amyloid plaques with sparse phosphorylated TDP-43 pathology. The survival rate was also reduced in Camk2a/TDP-43/APP/PSEN1 mice compared to other groups. This end-of-life study provides exploratory data to reach a better understanding of the role of TDP-43 hippocampal neuropathology in diseases with co-pathologies of TDP-43 proteinopathy and β-amyloidosis such as AD and limbic predominant age-related TDP-43 encephalopathy (LATE).

Arginine vasopressin (AVP) is a chemical signal in the brain that influences cerebral vascular resistance and brain water permeability. Increases in AVP contribute to the pathophysiology of brain edema following traumatic brain injury (TBI). These effects are mediated through AVP V1a receptors that are expressed in cortical and subcortical brain areas. This exploratory study characterizes the effects of a novel, V1a receptor antagonist, AVN576, on behavioral and magnetic resonance imaging (MRI) measures after severe TBI. Male Sprague Dawley rats were impacted twice producing contusions in the forebrain, putative cerebral edema, and cognitive deficits. Rats were treated with AVN576 after initial impact for 5 days and then tested for changes in cognition. MRI was used to assess brain injury, enlargement of the ventricles, and resting state functional connectivity. Vehicle treated rats had significant deficits in learning and memory, enlarged ventricular volumes, and hypoconnectivity in hippocampal circuitry. AVN576 treatment eliminated the enlargement of the lateral ventricles and deficits in cognitive function while increasing connectivity in hippocampal circuitry. These data corroborate the extensive literature that drugs selectively targeting the AVP V1a receptor could be used to treat TBI in the clinic.

Tritiated arginine8-vasopressin [( 3H]AVP) was used to identify specific binding sites for this neuropeptide in the CNS of the golden hamster. [3H]AVP binding sites were concentrated in the dorsal, ventral and lateral septum, bed nucleus of the stria terminalis (BNST), central amygdala, hippocampus, dorsal thalamic nuclei, anterior cingulate gyrus and endopiriform nucleus. Septal-BNST [3H]AVP binding sites were further characterized using membrane preparations. Saturation analysis in septal-BNST membranes resulted in a Bmax of 12.4 +/- 0.82 fmol/mg protein and a Kd of 2.5 +/- 0.36 nM. Pharmacological studies indicate that the binding site in the septum-BNST membranes shows selectivity similar to a V1-type vasopressin receptor. Binding characteristics were similar to those obtained from crude septal membranes prepared from adult Long-Evans rat.

Microinjection of neuropeptide Y (NPY) into the suprachiasmatic region of the hypothalamus (SCN) phase shifted the circadian activity rhythm of hamsters housed in constant light. NPY advanced the phase when injected during the 12 h that preceded the daily onset of activity and tended to phase delay the activity cycle when injected during the 12 h after activity onset. In contrast, injection of saline into the SCN or NPY into the ventricular system had no effect on circadian phase. These and other data suggest that NPY functions as a chemical messenger important for the light-dark cycle entrainment of circadian rhythms.

Microinjection of arginine-vasopressin (AVP) into the medial preoptic area of the hypothalamus of the hamster stimulates flank marking, a complex stereotypic motor behavior involved in olfactory communication. Microinjection of an antagonist of AVP, [1-deaminopenicillamine-2-(O-methyl)-tyrosine]arginine-vasopressin, into the same site blocks both the effect of microinjected AVP as well as the natural flank-marking behavior normally elicited by placing a hamster into the recently vacated home cage of another hamster. This finding supports the notion that AVP is a transmitter in the expression of flank marking.